GENE ONLINE|News &
Opinion
Blog

2021-10-05| Special

Taiwan’s Biotech Industry, Lackluster or Late Bloomer? A Breakdown of Policies, Hotspots, and Market Movements

by Kathy Huang
Share To
In this special series, we review the evolution of Taiwan’s biotech industry, focusing on key policies, bioclusters as well as the major deals surrounding licensing, mergers, and acquisitions. In the forthcoming articles, we will also present industry overviews, company analyses, and biotech investor interviews to depict the current landscape and predict future directions.

In the past, Taiwan built its ICT industry as a service provider which international brands could outsource. It can take a similar approach with its burgeoning CDMO industry to accumulate experience and technical knowledge. When considering manufacturing powerhouses such as South Korea and India, which have already established their CDMO markets, Taiwan’s industrial-scale...

GO Prime with only $1.49 now

LATEST
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial
2024-06-18
Company Presentations at BIO 2024 Inspire Partnering
2024-06-14
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-06-13
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
BIO Releases DEI Survey in Partnership with Korn Ferry
2024-06-11
EVENT
Scroll to Top